🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHas anyone dealt with mash biomarker panel? Page 6

Has anyone dealt with mash biomarker panel?

Dr.ObesityMed Mon, Jul 22, 2024 at 9:09 PM 27 replies 2,236 viewsPage 6 of 6
VanRx_Mike
Member
678
2,890
May 2024
Vancouver, CA
Aug 18, 2024 at 11:17 PM#26
kate.chem said:
One practical note: write down what you did and when, before you need it.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.

Correct me if the detail matters more than I have assumed.

18 16Dr.LeslieOBGYN, MikeNYC_runner and 15 others
Reply Quote Save Share Report
maya_sedona
Member
289
1,234
Sep 2024
Sedona, AZ
Aug 21, 2024 at 10:13 PM#27
kate.chem said:
One practical note: write down what you did and when, before you need it.

Agreed, and the size of the effect matters as much as its existence. Something real and small gets treated here as though it were real and decisive.

19 17NurseAsh_DET, BenResearch_OR, MikeKY_noInsulin and 16 others
Reply Quote Save Share Report
NauseaFreeNow
Member
345
1,234
Aug 2024
Indiana
Aug 24, 2024 at 9:07 PM#28
kate.chem said:
One practical note: write down what you did and when, before you need it.

Thank you — that is the clearest version of this I have read, and I have read a lot of them. Adding it to my notes with a link back to this thread.

20 18Dr.PulmRoch, maya_sedona, stefan_berlin and 17 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Aug 27, 2024 at 7:59 PM#29

Clinical perspective, offered as context rather than as advice. Worth answering the question that was asked rather than the one behind it. The narrow version usually has an answer; the broad version usually does not, and answering the broad one is how a thread stops being useful.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

21 19chris_chi24, tampaLisa73, KarenAZ_mom and 18 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Aug 30, 2024 at 6:50 PM#30

Closing the loop on my own question.

Closing this out. What actually changed my mind was the point about waiting for a trend instead of reading a single measurement, which is embarrassing in hindsight and worth saying anyway.

43 16A1cHero_PHX, Dr.RenalNash, LipidDoc_ATL and 40 others
Reply Quote Save Share Report
1456

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register